Voices
Stephen V Liu: Important ASCO26 Update in Atypical EGFR Mutant NSCLC
Stephen V Liu and Joel W. Neal

Stephen V Liu: Important ASCO26 Update in Atypical EGFR Mutant NSCLC

Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:

”Dr. Joel W. Neal shows OS of amivantamab + lazertinib in NSCLC with atypical EGFR mutations. RR 57%, PFS 19.5m, OS 41m with 2y OS rate 72%. Important update from ASCO26.”

Stephen V Liu: Important ASCO26 Update in Atypical EGFR Mutant NSCLC

Other Articles Featuring Stephen V Liu on OncoDaily.

ASCO26 cancer Joel W. Neal Lung cancer NSCLC OncoDaily Oncology Stephen V Liu